Book an Appointment
Call +27 (0)11 718 3004
Cancer cell vaccines is a therapy being increasingly used in Integrative cancer therapies.
We at Dr Golding’s Medical practice facilitate cancer cell vaccine therapy through a Greek lab known as rgcc-genlab
For those individuals wishing to entertain the idea of cancer cell vaccine therapy locally, we have the necessary Doctors available to consult with (a tissue biopsy is necessary for such dendritic cell vaccines.)
Dendritic Cells and Costimulatory Molecules: Scientists can use a type of white blood cell known as a dendritic cell to make cancer treatment vaccines. Dendritic cells are powerful stimulators of immune responses. They process and present cancer-associated antigens to T cells and B cells, and they produce costimulatory molecules that enhance the cell-killing properties of killer T cells.
This can be arranged locally.
Short Oligonucleotide Technique (SOT) has shown to be a very effective cancer support technique from our member patients experience over the last 9 years (2009). Minimum of 1,410 patients (ages 3-90 yo, a wide variety of cancers stages 1-4) and a minimum of 2,450 doses of SOT given as of today, (31.12.2017). Approximately 72% are still doing well. The most doses for 2 patients (to date) has been 9 and both are still doing extremely well.
We have available the SOT for ALL viral infections (Hepatitis B & C, EBV, HIV, CMV, HPV and so on), and for Lyme’s disease.
A similar technique called antisense has been known since 1978 and used since 1998. However, there are distinctive differences between antisense (as traditionally used) and SOT.
SOT is not a genetic therapy, as is most antisense treatments and no genotoxic (chemo) drugs are used. R.G.C.C.-Labs uses mRNA’s to only influence certain gene expressions not to change genetic structure. R.G.C.C.-labs uses mRNA expression fingerprinting to identify certain gene expression patterns as targets but without influence to the genetic structure (known as epigenetic). Based on this analysis R.G.C.C.-Labs uses the analysis of the individuals CTC’s/CSC’s and rarely from biopsies of the tumor, to generate the SOT (individualized). As of today, following extensive searches, we know of no one or other entity using this type of technique this way anywhere in the world.
SOT can induce apoptosis (cell death) in the CTC’s, CSC’s (circulating cancer tumor & stem cells) and ALL primary and metastatic tumors (regardless of size, and can cross the blood brain barrier with ease). SOT will remain active in the blood stream for approximately 20-24 weeks (maybe longer) per dose. Because, the mRNA actually features a stealth like ability that keeps the body from recognizing and destroying it by RNase. SOT will work 24/7 and has no decreased efficacy with any concurrent technique except rarely chemotherapy and/or radiation.
Only 3 full or 6 (½) SOT doses are allowed in any 12-month period from the date of first dose. We can use them again, with the same restrictions, if necessary, after the first 12-month period is completed. Since the SOT truly has a stealth characteristic (totally un-noticed by the body RNase) we do not want an over accumulation of these molecules to occur in anyone receiving this technique. Thus, we use only 3 full or 6 (½) per 12-month period per patient and can be used for years if necessary to help control cancer.
There have never been any anaphylactic reactions at all, from this procedure. The most we have seen is 1 maybe 2 mild headaches lasting about 1-2 hours and no residuals. Each dose will take about 1.5 hours to administer. Before each infusion, you will be given a very low dose of a short acting steroid (dexamethasone) and Zantac (anti-nausea) to further avoid even the rare mild issues.
Caution must be used with patients that have many tumors and/or large tumor sizes (depending on location) or tumors located in organs where apoptotic (cell death) induced edema may have a substantial negative impact on vital functions. In these cases, it is more efficacious to proceed slower (more time between doses) of SOT administration to eliminate or greatly reduce any potential risks. The above will apply to all forms of lymphomas and leukemias. We need to know the cell count (OncoCount or OncoTrace) and all areas of involved lymph node and sizes before starting. A recent PET/CT or CT with contrast, no older than 30-45 days. What we are trying to prevent is TLS (tumor lysis syndrome) or lactic acidosis which is more common in leukemias and lymphomas with high cell counts and/or very large lymph nodes, depending on size and number.
The end goal for this technique is to have the CTC’s/CSC’s (using R.G.C.C. OncoCount Test) show a maximum of <2 cells per ml and lower is always better (The absolute ideal is a “0” cell count and all negative markers) . Also, showing stability of all tumors (based on repeat scans and/or any blood markers you may use).
I understand there have been no warranties, assurances or guarantees of successful outcomes made to me.
Metastatic growth in distant organs is the major cause of cancer mortality. The development of metastasis is a multistage process with several rate-limiting steps1. Although dissemination of tumor cells seems to be an early and frequent event2, the successful initiation of metastatic growth, a process termed ‘metastatic colonization’, is inefficient for many cancer types and is accomplished only by a minority of cancer cells that reach distant sites. Prevalent target sites are characteristic of many tumor entities, suggesting that inadequate support by distant tissues contributes to the inefficiency of the metastatic process. Here we show that a small population of cancer stem cells is critical for metastatic colonization, that is, the initial expansion of cancer cells at the secondary site, and that stromal niche signals are crucial to this expansion process. We find that periostin (POSTN), a component of the extracellular matrix, is expressed by fibroblasts in the normal tissue and in the stroma of the primary tumour. Infiltrating tumour cells need to induce stromal POSTN expression in the secondary target organ (in this case lung) to initiate colonization. POSTN is required to allow cancer stem cell maintenance, and blocking its function prevents metastasis. POSTN recruits WNT (Wingless/integrase-1) ligands and thereby increases WNT signaling in cancer stem cells. We suggest that the education of stromal cells by infiltrating tumor cells is an important step in metastatic colonization and that preventing de novo niche formation may be a novel strategy for the treatment of metastatic disease.
Nature 481,85–89(05 January 2012) doi:10.1038/nature10694
“Cancer lethality is mainly due to the onset of distant metastases and refractoriness to chemotherapy. Growing evidence indicates that a cellular subpopulation with stem cell-like features, commonly referred to as cancer stem cells (CSC’s), is critical for tumor generation and maintenance”.
Maugeri-Saccà M, Vigneri P, De Maria R. Cancer Stem Cells and Chemosensitivity. Clin Cancer Res. 2011 Aug 1;17(15):4942-7. doi: 10.1158/1078-0432.CCR-10-2538.
“Thus, research must be directed at the relevant cell populations as identified through functional assays, the ultimate goal being the rational development of therapies that interfere with the oncogenic program within the CSC’s.”
Vincent T., Jr. DeVita, Theodore S. Lawrence, Steven A. Rosenberg – Cancer: Principles & Practice of Oncology: Primer of the Molecular Biology of Cancer, Lippincott Williams & Wilkins; 1 Pap/Psc edition May 2011, Page 163, 164.
At what size do tumors develop angiogenesis and are then able to metastasize?
Answer: ONLY 1-2 mm. …most primary solid tumors probably go through a prolonged state of avascular, and apparently dormant, growth in which the maximum size attainable is ~1–2 mm in diameter. Up to this size, tumor cells can obtain the necessary oxygen and nutrient supplies they require for growth and survival by simple passive diffusion; (ii) these microscopic tumor masses can, in some way, eventually switch on angiogenesis by recruiting surrounding mature host blood vessels to begin sprouting new blood vessel capillaries which grow toward, and eventually infiltrate the tumor mass, thus setting in motion the potential for relentless expansion of the tumor mass and hematogenous metastatic spread as well…
Robert S. Kerbel, Tumor angiogenesis: past, present and the near future, Carcinogenesis (2000) 21(3): 505-515 doi:10.1093/carcin/21.3.505.
LIFE STYLE: BODY, MIND, SPIRIT—Never forget, this is the foundation for ALL health!
LIFE PURPOSE & INTENTIONS, LIFE PASSION, THOUGHTS, BELIEFS, TALK, ACTION, BREATHING, DRINKING, EATING, MOVING, ELIMINATION, PLAY, HAVE FUN, RESTING, SPIRITUALLY SATISFIED, STRESS IMPACT MODIFICATION.
APOPTOSIS INDUCER – SOT (production period: 8 working days)
RGCC Therapy: In order to receive an RGCC therapy, the patient has to perform or have performed any RGCC test with a positive CTC count within the last 6 months.
-Patients with NO CELLS (in results) cannot receive any therapy.
VIRUS ANTAGONIST – SOT (production period: 8 working days)
RGCC Virus: For virus therapy the patient should perform for a Prime-Spot test or provide us any Virus specific Lab-results
-Patient with NEGATIVE results (by PrimeSPOT) or in Lab-results cannot receive any therapy
Whole tumor cells are a very simple approach to vaccination and can potentially be administered directly, without the need for dendritic cells. Live tumors cells are however poorly immunogenic and are shown to secrete soluble factors, such as vascular endothelial growth factor to suppress DCs differentiation and maturation.
A widely used and straightforward method of tumor cell preparation already used in clinical trials is necrotic whole tumor cell lysate. Whole tumor cells can be made necrotic by several methods. These methods generate cell material that contains a crude mixture of all kinds of cellular components including fragments of the destroyed cellular membrane, intracellular organelles such as mitochondria, and cellular RNA and DNA. Necrotic tumor cells have been shown to induce partial maturation in DC without further addition of maturation stimuli, probably due to the abundance of heat shock proteins which are released from dead cells after primary necrosis.
Tumor cells express a whole array of Tumor Associated Antigens (TAA) that are both characterized and uncharacterized, and this rich source of antigens contains epitopes of both CD8+ cytotoxic T cells (CTLs) and CD4+ T helper cells. This is important, as the parallel presentation of both MHC Class I and II restricted antigens would help to generate a stronger overall anti-tumor response and long term CD8+ T cell memory via CD4+ T cell help.
RGCC’s vaccine prep uses tumor cell antigens that are produced from the patients’ isolated circulating tumor cells. Tumor cells from each patient potentially carry gene mutations encoding for unique TAAs that are important in stimulating effective and long-lasting anti-tumor responses in the patient.
We need only once fresh sample of 15-20ml and Medical Form fully completed (Request Here).
With this blood sample we will produce six (6) dosages liquid form or 1 dose powder form ( powder you can storage in a shady place with room temperature and when you want to make the 6 doses you put 6ml water for injection and shake it gently with the syringe needle). The therapy will be for an intravenous and a subcutaneous treatment.
When you want to start
1 Week After
1 Week After
21 Day After
1 Week After
1 Week After